These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9070155)

  • 1. The impact of maternal age on the cost effectiveness of Down's syndrome screening.
    Dunstan FD; Nix AB
    Br J Obstet Gynaecol; 1997 Feb; 104(2):269-70. PubMed ID: 9070155
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of maternal age on the cost effectiveness of Down's syndrome screening.
    Torgerson DJ
    Br J Obstet Gynaecol; 1996 Jun; 103(6):581-3. PubMed ID: 8645654
    [No Abstract]   [Full Text] [Related]  

  • 3. Maternal serum screening policy for Down's syndrome.
    Cuckle H
    Lancet; 1992 Sep; 340(8822):799. PubMed ID: 1356219
    [No Abstract]   [Full Text] [Related]  

  • 4. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome.
    Shackley P; McGuire A; Boyd PA; Dennis J; Fitchett M; Kay J; Roche M; Wood P
    J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost effectiveness analysis of prenatal screening of trisomy 21 by maternal serum markers (hCG)].
    Seror V; Moatti JP; Muller F; Le Gales C; Boue A
    J Gynecol Obstet Biol Reprod (Paris); 1992; 21(8):915-22. PubMed ID: 1491137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marginal costs and benefits.
    Torgerson DJ; Spencer A
    BMJ; 1996 Jan; 312(7022):35-6. PubMed ID: 8555859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-benefit analysis of the prevention of Down's syndrome by means of prenatal diagnosis during early pregnancy].
    Flatz VG
    Fortschr Med; 1978 Jun; 96(24):1255-6, 1295. PubMed ID: 149085
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening programme for prevention of Down's syndrome.
    Stein Z; Susser M; Guterman AV
    Lancet; 1973 Feb; 1(7798):305-10. PubMed ID: 4119182
    [No Abstract]   [Full Text] [Related]  

  • 10. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
    Piggott M; Wilkinson P; Bennett J
    J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies.
    Gilbert RE; Augood C; Gupta R; Ades AE; Logan S; Sculpher M; van Der Meulen JH
    BMJ; 2001 Aug; 323(7310):423-5. PubMed ID: 11520837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
    Crossley JA; Aitken DA; Berry E; Connor JM
    J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Down's syndrome: experience in an inner city health district.
    Saridogan E; Djahanbakhch O; Naftalin AA
    Br J Obstet Gynaecol; 1996 Dec; 103(12):1205-11. PubMed ID: 8968237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of maternal age on the cost effectiveness of Down's syndrome screening.
    Macintosh MC
    Br J Obstet Gynaecol; 1996 Nov; 103(11):1175-7. PubMed ID: 8917017
    [No Abstract]   [Full Text] [Related]  

  • 16. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    Health Technol Assess; 1998; 2(1):i-iv, 1-112. PubMed ID: 9561893
    [No Abstract]   [Full Text] [Related]  

  • 17. The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population.
    Ford C; Moore AJ; Jordan PA; Bartlett WA; Wyldes MP; Jones AF; MacKenzie WE
    Br J Obstet Gynaecol; 1998 Aug; 105(8):855-9. PubMed ID: 9746377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevention of Down's syndrome in the south western region of England 1975-1985.
    Wilson N; Bickley D; McDermott A
    West Engl Med J; 1990 Mar; 105(1):15-7. PubMed ID: 2141994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevention of Down's syndrome.
    Alberman E
    Dev Med Child Neurol; 1975 Dec; 17(6):793-5. PubMed ID: 128482
    [No Abstract]   [Full Text] [Related]  

  • 20. Down's syndrome screening: equal risks for all?
    Bishop J; Dunstan F; Nix B
    Br J Obstet Gynaecol; 1996 Apr; 103(4):392. PubMed ID: 8605146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.